Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein Wnt-7a (WNT7A)
- Target
- WNT7A
- Molecular classification
- Secreted signaling protein, Wnt ligand, Developmental regulator, Other (as it is not a classical receptor, enzyme, transporter, or transcription factor)
01
Overview
Protein Wnt-7a (WNT7A) is a secreted glycoprotein that acts as a ligand within the Wnt signaling cascade, binding Frizzled family receptors to regulate β-catenin-dependent gene transcription and alternative non-canonical pathways. It is essential for embryonic limb patterning, tissue regeneration, neural development, and maintenance of the blood-brain barrier. Mutations disrupt limb and organ development, as seen in syndromes like Fuhrmann. Aberrant WNT7A signaling promotes cancer cell proliferation, and its pathway (often involving FZD7/JAK1/STAT3 or Wnt/β-catenin axes) is a target for investigational therapy. Therapeutic intervention requires balanced modulation due to its role in normal physiology and the potential for wide-ranging side effects
- Other names
- Wnt family member 7AWNT7AProtein Wnt-7aProto-oncogene Wnt7a proteinSANTOSWingless-type MMTV integration site family, member 7AWnt7a
02
Mechanism of action
Inhibition of WNT7A secretion (Porcupine inhibitors) Blockade of Wnt-Frizzled interaction (Frizzled antagonists/antibodies) Interference with β-catenin signaling (canonical pathway blockers)
03
Biological functions
Embryonic developmentCell fate specificationTissue regenerationSignal transduction (via Frizzled receptor activation)Cell proliferationCell differentiationDorsoventral limb patterningBlood-brain barrier regulation
04
Disease associations
Cancer (e.g., ovarian, endometrial, head and neck squamous cell carcinoma)Developmental syndromes (e.g., Fuhrmann syndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia)Neurodevelopmental disordersCardiovascular disease (via angiogenesis and blood-brain barrier regulation)
05
Safety considerations
Broad physiological role—systemic inhibition may cause developmental and regenerative deficitsOn-target toxicity—potential for adverse effects in bone, neural, and reproductive tissuesCancer risk—modulation can have oncogenic or tumor-suppressive effects depending on tissue context
06
Interacting drugs
Currently, there are no approved small-molecule drugs directly targeting WNT7A, but research is ongoing for: Porcupine inhibitors (indirectly affect Wnt ligand secretion)
2 more in the full profile.
07
Biomarkers
WNT7A expression levels (for patient selection or prognosis in cancer and developmental disorders)Phosphorylated STAT3 (correlative biomarker in HNSCC)
Beyond the preview
Go deeper on Protein Wnt-7a (WNT7A).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Protein Wnt-7a (WNT7A).